MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
|06/27/14||MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes|
|VALENCIA, Calif., June 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food & Drug Administration (FDA) has approved AFREZZA® (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus.
"Approval of AFREZZA is an important milestone for MannKind, as today's FDA action validates the years of clinical research and commitment that powered the development of this unique therapy," said Alfred Mann, Chief... |
|05/27/14||MannKind to Present at Upcoming Conferences|
|VALENCIA, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences.
Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 2:30 pm (ET) in New York, New York.
Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014 at 11:20 am (PT) at the Terranea Resort in Rancho Palos Verdes, Califo... |
|05/12/14||MannKind Corporation Reports 2014 First Quarter Financial Results|
|Conference Call to Begin Today at 5:00 PM ET
VALENCIA, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2014.
For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first quarter of 2013, an increase of $5.0 million. Research and development (R&D) expenses were $26.2 million for the first quarter of 2014, compared to $26.4 million for t... |
|05/07/14||MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference|
|VALENCIA, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 8:40 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Compan... |